Tommi Alcorn
Nurse Practitioner · Houston, MONPI 1538717871
Payments from drug & device makers
Across 122 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$360
- AstraZeneca$282
- Otsuka America Pharmaceutical, Inc.$180
- Regeneron Healthcare Solutions, Inc.$165
- Takeda Pharmaceuticals U.S.A., Inc.$144
- Boehringer Ingelheim$127
- plus $993 from 20 others
What the payments were for
- Food & beverage$2,23699%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $360 |
| AstraZeneca | 16 | $282 |
| Otsuka America Pharmaceutical, Inc. | 10 | $180 |
| Regeneron Healthcare Solutions, Inc. | 6 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $144 |
| Boehringer Ingelheim | 7 | $127 |
| Grifols USA, LLC | 7 | $114 |
| Amgen | 6 | $110 |
| Novartis | 7 | $102 |
| Sanofi | 3 | $71 |
| Lundbeck LLC | 3 | $70 |
| Verona Pharma, Inc. | 3 | $69 |
| Pfizer | 3 | $68 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Baxter Healthcare | 1 | $46 |
| Lilly USA, LLC | 2 | $46 |
| Insulet Corporation | 2 | $41 |
| AbbVie | 3 | $38 |
| Exact Sciences | 2 | $36 |
| Dexcom, Inc. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Merck | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Electromed, Inc. | 1 | $14 |
| Bayer | 1 | $12 |
How this compares
$2,250 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $66,531 |
| FarxigaDapagliflozin Propanediol | 59 | $50,230 |
| TrulicityDulaglutide | 32 | $36,734 |
| JardianceEmpagliflozin | 16 | $25,848 |
| EliquisApixaban | 35 | $25,307 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $25,224 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $23,822 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $15,497 |
| XareltoRivaroxaban | 16 | $13,600 |
| RexultiBrexpiprazole | 13 | $13,379 |
| JanuviaSitagliptin Phosphate | 13 | $11,526 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,205 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,063 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $2,928 |
| Celecoxib | 70 | $2,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $360 | $66,53158 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $282 | $60,29475 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $46 | $37,79859 claims |
| Boehringer IngelheimJardiance | $127 | $25,84816 claims |
| PfizerEliquis | $68 | $25,30735 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $180 | $13,37913 claims |
| MerckJanuvia | $15 | $11,52613 claims |
| GSKTrelegy Ellipta | $14 | $10,20516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.
Other nurse practitioner in Houston
- Aeron SheffieldChesterfield$269K
- Rachel ImperatoOsage Beach$260K
- Matthew BrunsBridgeton$126K
- Michelle DickensSpringfield$59K
- Robert HafnerKansas City$47K
- Tracey CarpenterChesterfield$47K
- Laura GrantSaint Charles$34K
- Courtney JefferyKansas City$24K
- Carrie Roth BettlachSaint Louis$21K
- Amanda HumbersFarmington$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.